Aclaris Therapeutics ACRS Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's total costs & expenses?
- Aclaris Therapeutics (ACRS) reported total costs & expenses of $24.19M in Q1 2026.
- How has Aclaris Therapeutics's total costs & expenses changed year-over-year?
- Aclaris Therapeutics's total costs & expenses increased by 23.8% year-over-year, from $19.54M to $24.19M.
- What is the long-term trend for Aclaris Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Aclaris Therapeutics's total costs & expenses has grown at a -3.3% compound annual growth rate (CAGR), from $96.48M to $84.2M.
- What does total costs & expenses mean?
- The aggregate of all operating and non-operating costs incurred by the company during the reporting period, including research, development, administrative, and licensing expenses. This metric serves as a primary measure of the company's total burn rate and operational scale. Tracking this figure is essential for evaluating the company's cost management efficiency and its runway toward profitability.